Kristina Lindemann, Head of the Gynecological Oncology Center at Oslo University Hospital, shared a post on LinkedIn:
Here are the results of the AGO-OVAR 2.29/ENGOT-ov34 study, published in Journal of Clinical Oncology.
- No significant OS eller PFS improvement by adding atezolizumab to chemotherapy in patients with platinum-resistant tubo-ovarian carcinoma.
- Weekly paclitaxel plus bevacizumab is the strongest backbone in this group of patients.
- More on immunotherapy to be learned from the phase 3 ENGOT-ov65/KEYNOTE-B96 trial.
For the opportunity to represent NSGO-CTU in this multicenter study thanks to the strong recruitment in Norway. Gratulation to all co-investigators and to the AGO Studiengruppe and ENGOT for fantastic leadership.”
Title: Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial
Authors: Philipp Harter, Frederik Marmé, Andrés Redondo, Alexander Reuss, Kristina Lindemann, Christian Kurzeder, Els Van Nieuwenhuysen, Christian Marth, Klaus Pietzner, Isabelle Ray-Coquard, Carmen Garcia-Duran, Goda Jonuskiene, Florian Heitz, Charlotte Béllier, J. Alejandro Pérez-Fidalgo, Ahmed El-Balat, Frédéric Selle, Ignacio Romero, Pauline Wimberger, Philippe Follana, Beatriz Pardo, Nikolaus de Gregorio, Florence Joly, Lydia Gaba, Alexander Burges, Michel Fabbro, Annette Hasenburg, Tanja Fehm, Barbara Schmalfeldt, Patricia Pautier
Read The Full Article on Journal of Clinical Oncology
More posts featuring Kristina Lindemann on OncoDaily.